Table 23Outcomes by length of time interval in stable population assessing BNP

Outcome MeasuresFollowup Months
123456789101112131415161718192021222324
All-cause mortality
Vrtovec,261 2003
Ralli,263 2005
Horwich,262 2006
Boffa,268 2009*
Meyer,264 2005
Adlbrecht,269 2009
Neuhold,271 2008
Scardovi,270 2008*25->
Bermingham,274 201133->
Moertl,275 2009**68->
Cardiovascular mortality
Vrtovec,261 2003
Cardiovascular mortality (continued)
Vrtovec,222 2008
Heart failure hospital admission
Bermingham,274 201133->
Composite of cardiovascular mortality and cardiovascular morbidity
Kruger,265 2005*
Composite of all-cause mortality and cardiovascular morbidity
Horwich,262 2006
Boffa,268 2009
Kozdag,266 2010
Scardovi,273 2007
Popescu,272 2007
Dries,267 201030->
Composite of all-cause mortality and all-cause morbidity
Bermingham,274 201133->

XI vertical line indicates intermittent endpoint measurement

*

mean;

**

median; measured by not used;

->study duration and endpoint greater than 24 months

From: Results

Cover of Use of Natriuretic Peptide Measurement in the Management of Heart Failure
Use of Natriuretic Peptide Measurement in the Management of Heart Failure [Internet].
Comparative Effectiveness Reviews, No. 126.
Balion C, Don-Wauchope A, Hill S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.